META-ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
Author(s)
Neil S Hawkins, PhD, Director1, Alyson Huntley, PhD, Systematic Reviewer2, James Eaton, MSc, Associate Health Economist21Oxford Outcomes (UK), Oxford, United Kingdom; 2 Oxford Outcomes (UK), Oxford, Oxfordshire, United Kingdom
OBJECTIVES To assess the comparative efficacy of biologics for the treatment of moderate to severe psoriasis. METHODS A systematic literature review was conducted to identify all randomized, controlled trials (until October 2008) evaluating the efficacy of approved biologics (adalimumab, efalizumab, etanercept, and infliximab) for the treatment of moderate to severe psoriasis. As regulatory approval of ustekinumab in this indication is anticipated shortly, three Phase 3 trials of ustekinumab were also included in this review. A network meta-analysis (NMA) conducted on the ordered probit scale was conducted to evaluate the comparative efficacy of the biologics based on the Psoriasis Area and Severity Index (PASI) responder endpoints. The absolute probability of PASI 50, 75 and 90 responses were estimated. RESULTS A total of 20 studies enrolling 10,108 psoriasis patients, including 1 head-to-head trial of etanercept and ustekinumab, were identified and included in the NMA. Thirteen studies evaluated TNF-alpha inhibitors (adalimumab =3, etanercept =6, infliximab =4), 5 studies evaluated T-cell modulators (efalizumab =5), and 3 studies evaluated ustekinumab. Baseline patient characteristics were comparable across the trials. The estimated mean PASI 75 responses were as follows: infliximab (mean 80%; 95% CI 70-87%), ustekinumab 90mg (74%; 68-80%), ustekinumab 45mg (69%; 62-75%), adalimumab (58%; 49-68%), etanercept 50mg biw (52%; 45-59%), etanercept 25mg biw (39%; 30-48%), efalizumab (26%; 21-32%), and supportive care/placebo (4%; 3-4%). CONCLUSIONS Based on this analysis, all of the active treatments produced a greater response rate than placebo. Ustekinumab and infliximab had the highest mean response rates followed in order by adalimumab, etanercept and efalizumab. However, there was considerable overlap in the 95% confidence intervals.
Conference/Value in Health Info
2009-05, ISPOR 2009, Orlando, FL, USA
Value in Health, Vol. 12, No. 3 (May 2009)
Code
PSS1
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Sensory System Disorders